Evaluation of factors that affect the response to Etanercept and Adalimumab in treatment of Joint involvement in patients with Spondyloarthropathy and Rheumathoid Arthritis

Evaluation of factors that affect the response to Etanercept and Adalimumab in treatment of Joint involvement in patients with Spondyloarthropathy and Rheumathoid Arthritis reffered to rheumatology clinics in Hamedan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240309061221N1

Enrollment

148

Registered

2024-03-27

Start date

2021-03-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Rheumatoid Arthritis. Condition 2: Ankylosing spondylitis. Rheumatoid arthritis with rheumatoid factor Ankylosing spondylitis

Interventions

Intervention 1: Intervention group: The first group is treated with Etanercept 50 mg once a week.Duration of the treatment is until the control of the symptoms. Intervention 2: Intervention group: The

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with a definitive diagnosis of rheumatoid arthritis or spondyloarthropathy who are candidates for receiving anti-TNF drugs.

Exclusion criteria

Exclusion criteria: The existence of contraindications for the administration of anti-TNF (history of MS, unexplained pancytopenia, heart failure class 2 and higher, presence of active infection, etc.) The patient's unwillingness to cooperate Inability to pay for medication

Design outcomes

Primary

Measure	Time frame
In Rheumatoid arthritis, DAS28 less than 3.3 is considered a response to treatment; In spondyloarthropathy, BASDAI above 4 is associated with high disease activity, and a decrease of 2 points after treatment is considered a response to treatment. Timepoint: 12 weeks after administration of the medication. Method of measurement: The response to treatment in patients with Rheumatoid arthritis is calculated using DAS-28 criteria and in Spondyloarthropathy patients using BASDAI criteria.	—

Measure

Time frame

In Rheumatoid arthritis, DAS28 less than 3.3 is considered a response to treatment; In spondyloarthropathy, BASDAI above 4 is associated with high disease activity, and a decrease of 2 points after treatment is considered a response to treatment. Timepoint: 12 weeks after administration of the medication. Method of measurement: The response to treatment in patients with Rheumatoid arthritis is calculated using DAS-28 criteria and in Spondyloarthropathy patients using BASDAI criteria.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Tahamoli Rudsari

Hamedan University of Medical Sciences

ahmadtahamoli@gmail.com+98 81 3838 0705

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026